Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.
Original title: “Roche extends China deal streak with $1B pact for RNAi obesity drug”
While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
Original title: “J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent”
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now "less likely."
Original title: “BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival”
Columnist G Shellye Horowitz's fashion piece, IV Couture, which was made from medical waste, is a 2026 RARE Artist finalist. That experience is part of why the RARE Artist contest means so much to me. A program of the RARE Foundation (formerly the EveryLife Foundation for Rare Diseases), it showcases the convergence of art and advocacy in the rare disease community. For me, it is an opportunity to portray feelings that words cannot always capture. “IV Couture is my way of expressing gratitude for the treatments that saved my life, while refusing to hide the reality of what survival requires. Rare disease advocacy, to me, means showing the full picture — the burden and the beauty — so the invisible parts of this life become impossible to look away from.” That meant going from 122 to 183 infusions per year — 61 more needle pokes. Each infusion takes about 20 minutes from start to finish, which added up to 1,220 more minutes, or 20 hours, spent infusing per year. Almost one full day. The burden is real. I am so excited to share that my piece, IV Couture, made the RARE Artist finals. I was diagnosed with superior mesenteric artery syndrome, another rare disease, and needed major surgery so I could eat again. This was not the first time I had to fight for a diagnosis. Years earlier, I fought to be diagnosed with hemophilia as a woman. Now I was fighting again, for a second rare diagnosis, while barely able to eat.
Original title: “IV Couture: Turning medical waste into rare disease advocacy”
For ultrarare diseases, the path to treatment is especially difficult. There may be only a handful of patients to study, little clinical evidence to guide trials and almost no commercial incentive to develop a therapy. Cousin and her collaborators have since built a comprehensive ADLD program, bringing together an international disease study and a dedicated ADLD Clinical Care Center to better understand the disorder, expand access to expert care and prepare for future treatment trials. "We're already seeing early signs of benefit in some of our neurodegenerative disease programs," Dr. Cousin says. "We're seeing encouraging biological signals that suggest these therapies are working as intended. Mayo Clinic researchers are using individualized approaches to diagnose and treat some of the world's rarest diseases, one patient at a time. Magnified hundreds of times, the cells carry the genetic variant responsible for KCNK9 imprinting syndrome, one of the rarest neurological diseases in the world. Dr. Cousin directs Mayo Clinic's N-of-1 Therapeutics Program, where scientists develop treatment strategies for diseases so rare they may affect only a single person. Margot Cousin, Ph.D., and Han Lee work at a laboratory bench in Mayo Clinic’s N-of-1 Therapeutics Program. The search for a KCNK9 treatment is one part of a much larger effort. Across other ultrarare diseases, Dr. Cousin and her collaborators are applying the same approach, and in some cases, have already carried it from laboratory research to experimental treatment. In 2025, they helped deliver the first custom experimental genetic treatments for Autosomal Dominant Leukodystrophy (ADLD) to a Mayo Clinic patient. The rare, fatal neurological disease slowly destroys the brain's white matter, disrupting the pathways that allow different regions of the brain to communicate.
Original title: “Mayo Clinic advances diagnosis and treatment of rare diseases”
Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
Original title: “Syndax ends fibrosis program for Niktimvo after mid-stage disappointment”
Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
Original title: “Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings”
New option offers acute treatment for adults with migraine
Original title: “SMC accepts AQUIPTA for eligible migraine patients in Scotland”
Final analysis shows durable outcomes in MF and SS
Original title: “MINT study results strengthen real‑world evidence for mogamulizumab”
oncostatin m deficiency a newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy
Original title: “Oncostatin M deficiency: A newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy.”